Protocol for Phase IIb Study of YM150. A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery. A Phase IIb study to Evaluate the Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects undergoing Elective Hip Replacement Surgery.

Trial Profile

Protocol for Phase IIb Study of YM150. A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery. A Phase IIb study to Evaluate the Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects undergoing Elective Hip Replacement Surgery.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Darexaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms ONYX-3
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 21 Apr 2012 Trial phase changed from II/III to II as reported by European Clinical Trials Database record.
    • 21 Apr 2012 Official Title amended as reported by European Clinical Trials Database record.
    • 28 Jul 2011 Results presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top